CBD Co. Wants Counterclaims Nixed In Epidiolex Patent Row
By Sam Reisman ( July 18, 2023, 3:58 PM EDT) -- British pharmaceutical firm GW Pharmaceuticals has urged a New Jersey federal judge to toss counterclaims lodged by InvaGen Pharmaceuticals in a patent dispute regarding GW's flagship CBD-derived epilepsy treatment Epidiolex....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.